Search

Displaying results 561 - 570 of 2955 in total
  1. Drug

    Vildagliptin

    go.drugbank.com/drugs/DB04876
    ApprovedInvestigational

    Vildagliptin (LAF237) is an orally active antihyperglycemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme. It is used to manage type II diabetes mellitus, where GLP-1 secretion and insulinotropic effects are i...

    Mixtures: VILDAGLIPTIN E METFORMINA SANDOZ, VILDAGLIPTIN E METFORMINA SANDOZProducts: VILDAGLIPTIN EG
  2. Drug

    Clidinium

    go.drugbank.com/drugs/DB00771
    Approved

    It is used for the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome.

    Mixtures: Nu-chlorax Capsules USP
  3. Drug

    Metoprolol

    go.drugbank.com/drugs/DB00264
    ApprovedInvestigational

    [A175162] Metoprolol was developed since 1969 by US Pharmaceutical Holdings I and FDA approved in 1978.[L5527]

    Products: METOPROLOLO EG, Metoprolol Succinate ER
  4. Drug

    Naloxegol

    go.drugbank.com/drugs/DB09049
    ApprovedInvestigational

    The advantage of naloxegol over the opioid antagonist naloxone is that its PEGylated structure allows for high selectivity for peripheral opioid receptors and lack of entry into the central nervous system … It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain.

  5. Drug

    Tyrothricin

    go.drugbank.com/drugs/DB13503
    ApprovedWithdrawn

    Moreover, tyrothricin possesses broad spectrum Gram-positive antibacterial and antifungal activity that has not seen many - if any - significant reportings of microbial resistance during the over 60 years

  6. Drug

    Eluxadoline

    go.drugbank.com/drugs/DB09272
    ApprovedInvestigational

    Marketed under the tradename Viberzi (FDA), eluxadoline is an antimotility agent that decreases bowel contractions, inhibits colonic transit, and reduces fluid/ion secretion resulting in improved symptoms … The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system and peripherally in the gastrointestinal system.

    Categories: mu-Opioid Receptor Agonist
  7. Drug

    Colestipol

    go.drugbank.com/drugs/DB00375
    Approved

    [FDA Label, F4555, F4567, L6262] … [FDA Label, F4555, F4567, L6262] The resultant lack of systemic exposure consequently means the medication generally demonstrates very few adverse effects inside the body.

  8. Drug

    Cephalexin

    go.drugbank.com/drugs/DB00567
    ApprovedInvestigationalVet approved

    [A179083,L6547] Cephalexin was approved by the FDA on 4 January 1971.[L6547]

    Products: LUPICEFF ER, CEFALON ® ER
  9. Drug

    Estetrol

    go.drugbank.com/drugs/DB12235
    ApprovedInvestigational

    Estetrol is the first new estrogen introduced to the USA in over 50 years and is the first approved estetrol product in the world. … [L33184] Estetrol (E4) is a native estrogen occurring naturally during pregnancy, but can be synthesized from a plant source and used for contraception.

  10. Drug

    Omega-3-acid ethyl esters

    go.drugbank.com/drugs/DB09539
    ApprovedInvestigational

    Omega-3-acid ethyl esters are currently marketed in the US, EU, and many other regions under the brand name Lovaza[FDA Label][L5849]. … acid-ethyl ester (EPA) and docosahexaenoic acid-ethyl ester (DHA) that are used in combination with changes in diet to lower triglyceride levels in adults with severe (≥ 500 mg/dL) hypertriglyceridemia[FDA

    Mixtures: ROSUVASTATINA E OMEGA 3 SPA SOCIET PRODOTTI ANTIBIOTICI, ROSUVASTATINA E OMEGA 3 SPA SOCIET PRODOTTI ANTIBIOTICI